Investigation into Geron Corporation: Potential Securities Law Violations
New York, NY – March 6, 2025 – Bragar Eagel & Squire, P.C., a renowned securities rights law firm, is currently scrutinizing potential claims against Geron Corporation (Geron or the Company) (NASDAQ: GERN) on behalf of the Company’s shareholders. The investigation revolves around allegations that Geron may have breached federal securities laws and/or engaged in unlawful business practices.
Background
Geron Corporation is a biotechnology company specializing in the discovery and development of therapeutics for aging and cancer. The Company’s lead program is a telomerase inhibitor, Imetelstat, which is being investigated for the treatment of myelofibrosis and other bone marrow diseases. In May 2021, Geron announced positive results from a Phase 3 clinical trial for Imetelstat in myelofibrosis, which sent the Company’s stock price soaring.
The Allegations
Bragar Eagel & Squire’s investigation focuses on whether Geron and certain of its executives and directors made false and/or misleading statements and failed to disclose material information to investors. Specifically, the firm is investigating whether Geron misrepresented the safety and efficacy data of Imetelstat, downplayed the risks associated with the drug, and failed to disclose material information regarding the drug’s development timeline and regulatory approval process.
Implications for Shareholders
If Geron is found to have violated securities laws, shareholders may be able to recover their losses through a class action lawsuit. The potential damages could be significant, as the Company’s stock price experienced a substantial increase following the positive Phase 3 trial results, only to experience a sharp decline in the wake of concerns regarding the drug’s safety and regulatory approval process.
Implications for the Biotech Industry
The investigation into Geron could have far-reaching implications for the biotech industry as a whole. If it is determined that Geron misrepresented the safety and efficacy data of Imetelstat, it could erode investor confidence in the sector and lead to increased regulatory scrutiny. Furthermore, it could set a precedent for future securities lawsuits against other biotech companies, potentially leading to increased litigation risks and costs.
Conclusion
The investigation into Geron Corporation is a developing story that could have significant implications for both the Company’s shareholders and the broader biotech industry. As the situation unfolds, it is crucial for investors to stay informed and seek the advice of qualified securities attorneys if they believe they may have potential claims. Bragar Eagel & Squire will continue to monitor the situation closely and provide updates as more information becomes available.
- Geron Corporation is under investigation for potential securities law violations
- The investigation concerns allegations of false and/or misleading statements and failure to disclose material information
- Shareholders may be able to recover losses through a class action lawsuit if Geron is found to have violated securities laws
- The investigation could have far-reaching implications for the biotech industry, potentially leading to increased regulatory scrutiny and increased litigation risks
